Cybrexa Therapeutics picks up $25m Series B

Cybrexa Therapeutics, an oncology-focused biotechnology company, has closed $25 million in Series B financing.

10 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles